Department of Psychiatry, Hanyang University Guri Hospital, Guri, Republic of Korea.
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
Adv Exp Med Biol. 2023;1411:209-224. doi: 10.1007/978-981-19-7376-5_10.
Major depression is impacted by the disruption of gut microbiota. Defects in gut microbiota can lead to microbiota-gut-brain axis dysfunction and increased vulnerability to major depression. While traditional chemotherapeutic approaches, such as antidepressant use, produce an overall partial therapeutic effect on depression, the gut microbiome has emerged as an effective target for better therapeutic outcomes. Recent representative studies on the microbiota hypothesis to explore the association between gut pathophysiology and major depression have indicated that restoring gut microbiota and microbiota-gut-brain axis could alleviate depression. We reviewed studies that supported the gut microbiota hypothesis to better understand the pathophysiology of depression; we also explored reports suggesting that gut microbiota restoration is an effective approach for improving depression. These findings indicate that gut microbiota and microbiota-gut-brain axis are appropriate new therapeutic targets for major depression.
重度抑郁症受肠道微生物群紊乱的影响。肠道微生物群的缺陷可导致微生物群-肠道-大脑轴功能障碍,并增加患重度抑郁症的易感性。虽然传统的化学治疗方法,如使用抗抑郁药,对抑郁症有整体的部分治疗效果,但肠道微生物组已成为改善治疗效果的有效靶点。最近关于微生物组假说的代表性研究探索了肠道生理学与重度抑郁症之间的关联,表明恢复肠道微生物组和微生物组-肠道-大脑轴可以缓解抑郁症。我们回顾了支持肠道微生物组假说的研究,以更好地理解抑郁症的病理生理学;我们还探讨了一些报告,表明肠道微生物组的恢复是改善抑郁症的有效方法。这些发现表明,肠道微生物组和微生物组-肠道-大脑轴是重度抑郁症的合适的新治疗靶点。